KSE - Delayed Quote KRW

SK Biopharmaceuticals Co., Ltd. (326030.KS)

104,100.00

-800.00

(-0.76%)

At close: 3:30:30 PM GMT+9

SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals

SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous system and oncology worldwide, announced a research collaboration agreement with ProEn Therapeutics, a biotech company dedicated to advancing oncology treatments, to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies (RPT).

PR Newswire 4 months ago

326030.KQ

326030.KS
-0.76%
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea's premier research institution dedicated to the study and advancement of radiological and medical sciences, to collaborate on discovering and developing preclinical radiopharmaceutical drug candidates.

PR Newswire 4 months ago

326030.KQ

326030.KS
-0.76%

Performance Overview

Return	326030.KS	KOSPI Composite Index (^KS11)
YTD	-6.30%	+3.63%
1-Year	+23.63%	-5.43%
3-Year	+19.93%	-8.06%